Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology

Metastatic Malignant Neoplasm in the Brain Clinical Trial

Official title:

Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04988009
• Other study ID #: 2020-0493
• Secondary ID: NCI-2020-0749320
• Status: Recruiting
• Start date: August 20, 2020
• Est. completion date: December 31, 2026

Study information

• Verified date: March 2024
• Source: M.D. Anderson Cancer Center
• Contact: Barbara J O'Brien, MD
• Phone: 713-794-4380
• Email: bjobrien[@]mdanderson.org
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study evaluates patient perceptions around quality of care through telemedicine in neuro-oncology. Studying questionnaires related to perceptions quality of care through telemedicine in patients with brain cancer may help doctors to improve the delivery of care through this modality.

Description:

PRIMARY OBJECTIVE:

I. To evaluate the patient-perceived quality of care by group (telemedicine versus in-person visits) in patients with central nervous system (CNS) cancer.

SECONDARY OBJECTIVES:

I. To characterize the visits provided by telemedicine compared to those in-person.

II. To contrast the average time spent on telemedicine visits compared to in-person visits, and the delay between visit order placement and visit occurring.

III. To evaluate the domains of patient care addressed on a telemedicine visit versus in-person visit per documentation, including (1) treatment planning, (2) symptom burden, (3) goals of care.

IV. To evaluate frequency of acute care sought (through emergency room or urgent care clinic) within 30 days of encounter in telemedicine visit versus (vs) in-person visit.

V. The impact of patient and clinical characteristics on perceived quality of care in the context of covariate-adjusted modeling.

OUTLINE:

Patients complete a survey related to their perceived quality of care via telephone and have their medical chart reviewed prospectively.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: December 31, 2026
• Est. primary completion date: December 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with a CNS tumors: this includes patients with primary brain tumors, brain metastases, and leptomeningeal disease

• Established patients with a follow up encounter with Neuro-Oncology at the Brain and Spine Center at the University of Texas MD Anderson Cancer Center; this encounter can be

• An in-person visit

• A telemedicine appointment

Exclusion Criteria:

• Encounter occurred with the assistance of official language translation support

• Patients with telephone encounters (without interactive video)

• New patient or consult visits

• Neither patient nor caregiver present during the visit are available or able to answer survey questions

Related Conditions & MeSH terms

• Brain Neoplasms
• Central Nervous System Neoplasm
• Central Nervous System Neoplasms
• Leptomeningeal Neoplasm
• Meningeal Neoplasms
• Metastatic Malignant Neoplasm in the Brain
• Neoplasms
• Nervous System Neoplasms
• Primary Brain Neoplasm

Intervention

Other:
• Electronic Health Record Review
Review of medical chart
• Survey Administration
Complete survey

Locations

Country	Name	City	State
United States	M D Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Survey response to question 6 of the quality of care survey ("I felt I received good medical care during this encounter")	Survey responses will be summarized by ordinal category as counts with percentages, separately by group. Will separately estimate the proportion of each ordinal level of each group with 95% confidence interval.	through study completion, an average of 1 year
Secondary	Quality of Care Survey	Will separately estimate the proportion of each ordinal level of each group with 95% confidence interval.	through study completion, an average of 1 year
Secondary	Patients and clinical characteristics	Differences between groups will be assessed by 2-sample 2-sided t-test and Mann-Whitney test, Fisher's exact test, or chi-square test.	Baseline
Secondary	Interactive time spent during visit	Will be summarized by group per mean, median, standard deviation, and range. Differences between groups will be assessed by t-test and Mann-Whitney test.	through study completion, an average of 1 year
Secondary	Time from visit order placement to visit occurring	Will be summarized by group per mean, median, standard deviation, and range. Differences between groups will be assessed by t-test and Mann-Whitney test.	through study completion, an average of 1 year
Secondary	Domains of patient care addressed during a visit, including treatment planning, symptom burden, and goals of care	Will be summarized as counts with percentages by group. Differences between groups will be assessed by chi-square test.	through study completion, an average of 1 year
Secondary	Incidence of acute care sought (through emergency room or urgent care clinic)	Will be summarized as counts with percentages by group. Differences between groups will be provisionally assessed by Fisher's exact test.	Within 30 days of encounter

External Links

•   University of Texas MD Anderson Cancer Center Website